MedPath

Paricalcitol

Generic Name
Paricalcitol
Brand Names
Zemplar
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
131918-61-1
Unique Ingredient Identifier
6702D36OG5
Background

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication

For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions
Secondary Hyperparathyroidism (SHPT)
Clinical Trials
Related News

Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2010-09-17
Last Posted Date
2013-09-05
Lead Sponsor
Danderyd Hospital
Target Recruit Count
36
Registration Number
NCT01204528
Locations
🇸🇪

Karolinska Institute at Danderyd University Hospital, Danderyd, Stockholm, Sweden

Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery

Phase 1
Terminated
Conditions
Mucinous Adenocarcinoma of the Rectum
Stage IIA Rectal Cancer
Stage IIB Rectal Cancer
Stage IIC Rectal Cancer
Stage IIIB Rectal Cancer
Stage IIIC Rectal Cancer
Interventions
Radiation: radiation therapy
Other: laboratory biomarker analysis
First Posted Date
2010-09-09
Last Posted Date
2018-07-02
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
2
Registration Number
NCT01197664
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2010-07-15
Last Posted Date
2013-05-21
Lead Sponsor
Indiana University
Target Recruit Count
16
Registration Number
NCT01163162
Locations
🇺🇸

Roudebush VA Medical Center, Indianapolis, Indiana, United States

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery

Phase 3
Completed
Conditions
Gastric Bypass
Parathyroid Hormone
Interventions
Drug: Placebo
First Posted Date
2010-06-07
Last Posted Date
2017-03-22
Lead Sponsor
Kerstyn C. Zalesin, M.D.
Target Recruit Count
49
Registration Number
NCT01138475
Locations
🇺🇸

William Beaumont Health Center, Royal Oak, Michigan, United States

Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Placebo
First Posted Date
2010-06-03
Last Posted Date
2012-01-25
Lead Sponsor
Erling Bjerregaard Pedersen
Target Recruit Count
30
Registration Number
NCT01136564
Locations
🇩🇰

Department of Medical Research, Holstebro, Denmark

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

Terminated
Conditions
Secondary Hyperparathyroidism
End-Stage Renal Disease
Interventions
First Posted Date
2010-06-02
Last Posted Date
2013-08-13
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
61
Registration Number
NCT01134315
Locations
🇺🇸

Site Reference ID/Investigator# 26748, Atlanta, Georgia, United States

🇺🇸

Site Reference ID/Investigator# 26769, Boston, Massachusetts, United States

🇺🇸

Site Reference ID/Investigator# 26749, Akron, Ohio, United States

and more 15 locations

Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis

Completed
Conditions
Parathyroid Hormone
Interventions
First Posted Date
2010-03-10
Last Posted Date
2011-09-21
Lead Sponsor
Abbott
Target Recruit Count
181
Registration Number
NCT01084538
Locations
🇭🇷

Site Reference ID/Investigator# 27525, Dubrovnik, Croatia

🇭🇷

Site Reference ID/Investigator# 27531, Imotski, Croatia

🇭🇷

Site Reference ID/Investigator# 6175, Karlovac, Croatia

and more 18 locations

Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease

Phase 3
Completed
Conditions
Chronic Kidney Disease
Interventions
First Posted Date
2010-02-19
Last Posted Date
2012-01-26
Lead Sponsor
Abbott
Target Recruit Count
216
Registration Number
NCT01071070
Locations
🇨🇳

Site Reference ID/Investigator# 35822, Wenzhou, China

🇨🇳

Site Reference ID/Investigator# 37722, Qingdao, China

🇨🇳

Site Reference ID/Investigator# 23485, Beijing, China

and more 9 locations

Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)

Phase 3
Completed
Conditions
Chronic Kidney Disease Stage 3 and 4
Interventions
Drug: Placebo
First Posted Date
2009-11-24
Last Posted Date
2018-07-02
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Target Recruit Count
47
Registration Number
NCT01020487

Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease

Phase 3
Terminated
Conditions
Coronary Artery Disease
Chronic Kidney Disease
Hypovitaminosis D
Secondary Hyperparathyroidism
Interventions
Drug: placebo
First Posted Date
2009-11-13
Last Posted Date
2014-05-20
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
10
Registration Number
NCT01012414
Locations
🇺🇸

Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy